Abstract
The Food and Drug Administration recently updated the safety warning concerning the association between statin therapy and new-onset diabetes mellitus (NODM). For prediabetes, little information is available for statins on cardiovascular outcome reduction and diabetogenic consequences. This study aimed to examine the risk of NODM and the reduction of cardiovascular events and death (MACE) after statin therapy in the prediabetic subjects. The medical and pharmacy claims of the prediabetic beneficiaries were retrieved from Taiwan National Health Insurance research database. The occurrence of NODM, MACE, and morbidity indexed by hospitalizations and emergency visits was ascertained by ambulatory and inpatient database. A propensity score-matched model was constructed for statin users and nonusers. During follow-up (4.1 ± 2.5 years), NODM and MACE occurred in 23.5% and 16.7%, respectively, of nonusers and 28.5% and 12.0%, respectively, of users. Statin therapy was associated with a greater risk of NODM (hazard ratio 1.20, 95% confidence interval 1.08 to 1.32) and less risk of MACE (hazard ratio 0.70, 95% confidence interval 0.61 to 0.80), both in dose-dependent fashions. The earlier and more persistent use correlated with the great...Continue Reading
References
Jan 30, 2007·Diabetes Care·Gregory A NicholsJonathan B Brown
Jan 15, 2008·Lancet·P M KearneyC Baigent
Jun 13, 2008·Current Medical Research and Opinion·Hyo-Soo KimPeter Yan
Feb 20, 2010·Lancet·Naveed SattarIan Ford
Mar 27, 2010·Journal of the American College of Cardiology·Earl S FordChaoyang Li
Nov 12, 2010·Lancet·UNKNOWN Cholesterol Treatment Trialists’ (CTT) CollaborationR Collins
Apr 2, 2011·Journal of the American College of Cardiology·David D WatersPhilip Barter
Apr 7, 2011·The Journal of Clinical Hypertension·Alan J Garber
May 6, 2011·Diabetes Care·Rafael Bitzur
Jun 23, 2011·JAMA : the Journal of the American Medical Association·David PreissKausik K Ray
Aug 10, 2011·The American Journal of Cardiology·Ralph A DeFronzo, Muhammad Abdul-Ghani
Aug 30, 2011·European Heart Journal·Peter S SeverUNKNOWN ASCOT Investigators
Feb 11, 2012·Journal of the American College of Cardiology·Scott M Grundy
Aug 14, 2012·Lancet·Paul M RidkerRobert J Glynn
Aug 14, 2012·Journal of the American College of Cardiology·Kang-Ling WangChern-En Chiang
Aug 29, 2012·European Heart Journal·Stefan D Anker, John J V McMurray
Oct 17, 2012·Diabetes Care·Andrew J KarterAlka M Kanaya
Dec 12, 2012·Journal of the American College of Cardiology·David D WatersTerje R Pedersen
Jan 29, 2013·The American Journal of Cardiology·Eliano Pio NavareseJacek Kubica
Mar 19, 2013·Journal of the American College of Cardiology·Therese TillinNish Chaturvedi
Citations
Jun 28, 2016·The Canadian Journal of Cardiology·G B John ManciniA Yashar Tashakkor
Jan 7, 2016·The American Journal of Cardiology·Seung-Woon RhaDong Joo Oh
Dec 1, 2015·Biochemical Pharmacology·Zhaoli LingXiaodong Liu
Oct 7, 2015·Clinical Pharmacology and Therapeutics·U AnyanwaguRichard Donnelly
Feb 5, 2015·Medical Hypotheses·M Sonal Sekhar, M K Unnikrishnan
Dec 9, 2014·Metabolism: Clinical and Experimental·Niki KatsikiChristos S Mantzoros
Jan 3, 2015·The American Journal of Cardiology·Anton P van de WoestijneFrank L J Visseren
Sep 4, 2015·Therapeutic Advances in Chronic Disease·Anastazia KeiMoses Elisaf
Apr 20, 2019·Diabetes, Obesity & Metabolism·Manju Bengaluru Jayanna, Jennifer G Robinson
Nov 23, 2019·Cardiovascular Diabetology·Han Saem JeongDo-Sun Lim
Sep 5, 2014·Current Opinion in Lipidology·Vasutakarn Chongthammakun, Richard A Krasuski
Apr 19, 2015·Current Opinion in Lipidology·Jennifer G Robinson
May 21, 2017·Scientific Reports·Fei LuoXiang-Ping Li
Jan 1, 2017·Metabolomics : Official Journal of the Metabolomic Society·Mona Elbadawi-SidhuRima Kaddurah-Daouk
Sep 12, 2019·Internal Medicine Journal·Anosh SivashanmugarajahAnthony Keech
Sep 13, 2019·Neurology India·Wang ZhaoShui-Ping Zhao
Sep 3, 2021·Vascular·Xuehui ZhangQuanming Zhao